Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma

Neoplasia (United States)

Volumn 16, Issue 10, 2014, Pages 874-882

  Marrero, Luis ^a   Wyczechowska, Dorota ^a   Musto, Alberto E ^b   Wilk, Anna ^a   Vashistha, Himanshu ^a   Zapata, Adriana ^a   Walker, Chelsey ^a   Velasco Gonzalez, Cruz ^c   Parsons, Christopher ^a   Wieland, Scott ^d   Levitt, Daniel ^d   Reiss, Krzysztof ^a   Prakash, Om ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d CytRx Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988009556     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.08.015     Document Type: Article

References (31)

1. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, and Platten M (2011). Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 13, 566-579.
2. Silber JR, Bobola MS, Blank A, and Chamberlain MC (2012). O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim Biophys Acta 1826, 71-82.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, and Bogdahn U, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, and Belanger K, et al (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
5. Oliva CR, Nozell SE, Diers A, McClugage III SG, Sarkaria JN, Markert JM, Darley-Usmar VM, Bailey SM, Gillespie GY, and Landar A, et al (2010). Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem 285, 39759-39767.
6. Soda Y, Myskiw C, Rommel A, and Verma IM (2013). Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med 91, 439-448.
7. Chamberlain MC (2011). Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 5, 117-129.
8. Weller M, Cloughesy T, Perry JR, and Wick W (2013). Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol 15, 4-27.
9. Misra A, Ganesh S, Shahiwala A, and Shah SP (2003). Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 6, 252-273.
10. Balmaceda C (1998). Advances in brain tumor chemosensitivity. Curr Opin Oncol 10, 194-200.
11. von Holst H, Knochenhauer E, Blomgren H, Collins VP, Ehn L, Lindquist M, Noren G, and Peterson C (1990). Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir 104, 13-16.
12. Lesniak MS, Upadhyay U, Goodwin R, Tyler B, and Brem H (2005). Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 25, 3825-3831.
13. Chen H, Qin Y, Zhang Q, Jiang W, Tang L, Liu J, and He Q (2011). Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur J Pharm Sci 44, 164-173.
14. Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D, Grauer O, Steinbrecher A, Hirschmann B, Brawanski A, and Dietmaier C, et al (2009). RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma-a phase II study. BMC Cancer 9, 308.
15. Ananda S, Nowak AK, Cher L, Dowling A, Brown C, Simes J, and Rosenthal MA (2011). Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci 18, 1444-1448.
16. Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P, Druckes P, Esser N, Drevs J, and Rognan D, et al (2002). Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. JMedChem45, 5523-5533.
17. Graeser R, Esser N, Unger H, Fichtner I, Zhu A, Unger C, and Kratz F (2010). INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs 28, 14-19.
18. Kratz F, Fichtner I, and Graeser R (2012). Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model. Invest New Drugs 30, 1743-1749.
19. Sanchez E, Li M, Wang C, Nichols CM, Li J, Chen H, and Berenson JR (2012). Anti-myeloma effects of the novel anthracycline derivative INNO-206. Clin Cancer Res 18, 3856-3867.
20. Unger C, Haring B, Medinger M, Drevs J, Steinbild S, Kratz F, and Mross K (2007). Phase I and pharmacokinetic study of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin. Clin Cancer Res 13, 4858-4866.
21. Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E, Scappaticci FA, Saplis RJ, Ekker SC, and Low WC, et al (2005). Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 12, 778-788.
22. Oh S, Tsai AK, Ohlfest JR, Panoskaltsis-Mortari A, and Vallera DA (2011). Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg 114, 1662-1671.
23. Roti Roti EC, Leisman SK, Abbott DH, and Salih SM (2012). Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent. PLoS One 7, e42293.
24. Heinze G, Gnant M, and Schemper M (2003). Exact log-rank tests for unequal follow-up. Biometrics 59, 1151-1157.
25. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, and Moreira PI (2009). Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16, 3267-3285.
26. Kratz F (2007). DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs 16, 855-866.
27. Cohen MH, Shen YL, Keegan P, and Pazdur R (2009). FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14, 1131-1138.
28. Kratz F (2008). Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132, 171-183.
29. Kratz F and Beyer U (1998). Serum proteins as drug carriers of anticancer agents: a review. Drug Deliv 5, 281-299.
30. Maeda H, Wu J, Sawa T, Matsumura Y, and Hori K (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65, 271-284.
31. Kremer P, Fardanesh M, Ding R, Pritsch M, Zoubaa S, and Frei E (2009). Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery 64, ons53-ons60 [discussion ons60-51].